Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients.

[1]  F. Carrat,et al.  How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. , 2008, Clinical chemistry.

[2]  D. Neau,et al.  Validation and Comparison of Simple Noninvasive Indexes for Predicting Liver Fibrosis in HIV-HCV-Coinfected Patients: ANRS CO3 Aquitaine Cohort , 2008, The American Journal of Gastroenterology.

[3]  Y. Ngo,et al.  An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load , 2008, PloS one.

[4]  F. Carrat,et al.  Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02. , 2008, Journal of hepatology.

[5]  Patrice Cacoub,et al.  Meta-analyses of FibroTest diagnostic value in chronic liver disease , 2007, BMC gastroenterology.

[6]  V. de Lédinghen,et al.  Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. , 2007, Clinical chemistry.

[7]  Patrice Faure,et al.  Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. , 2007, Journal of hepatology.

[8]  V. Soriano,et al.  Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. , 2007, The Journal of infectious diseases.

[9]  V. Paradis,et al.  Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. , 2007, Journal of hepatology.

[10]  F. Roudot-thoraval,et al.  Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines? , 2007, Journal of hepatology.

[11]  S. Pol,et al.  Liver‐related mortality in human‐immunodeficiency‐virus‐infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study) * , 2007, Journal of viral hepatitis.

[12]  A. Alberti,et al.  Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. , 2007, World journal of gastroenterology.

[13]  D. Capron,et al.  Noninvasive diagnosis of liver fibrosis by ultrasonic transient elastography (Fibroscan) , 2006, European journal of gastroenterology & hepatology.

[14]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[15]  V. Soriano,et al.  Management of chronic hepatitis B and C in HIV-coinfected patients. , 2006, The Journal of antimicrobial chemotherapy.

[16]  S. Lipshultz,et al.  Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. , 2006, Atherosclerosis.

[17]  F. Carrat,et al.  Hepatic steatosis in HIV–HCV coinfected patients: analysis of risk factors , 2006, AIDS.

[18]  F. Carrat,et al.  Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV , 2006, AIDS.

[19]  F. Oberti,et al.  A novel panel of blood markers to assess the degree of liver fibrosis , 2005, Hepatology.

[20]  Lungen Lu,et al.  Prediction of significant fibrosis in HBeAg‐positive patients with chronic hepatitis B by a noninvasive model , 2005, Hepatology.

[21]  J. Kench,et al.  Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. , 2005, Clinical chemistry.

[22]  J. Macías,et al.  Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes , 2005, Gut.

[23]  Albert Tran,et al.  Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus , 2005, Comparative hepatology.

[24]  N. Afdhal,et al.  Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. , 2005, Journal of hepatology.

[25]  R. Gandhi.  Guideline watch. New guidelines on treating chronic hepatitis B and C in HIV-coinfected patients. , 2005, AIDS Clinical Care.

[26]  V. Wong,et al.  Identification of Chronic Hepatitis B Patients without Significant Liver Fibrosis by a Simple Noninvasive Predictive Model , 2005, American Journal of Gastroenterology.

[27]  Thomas K. Hazlet,et al.  Global Epidemiology of Hepatitis B Virus , 2004, Journal of clinical gastroenterology.

[28]  D. Thabut,et al.  Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C , 2004, Comparative hepatology.

[29]  D. Ganem,et al.  Hepatitis B virus infection--natural history and clinical consequences. , 2004, The New England journal of medicine.

[30]  J. Kalbfleisch,et al.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.

[31]  T. Poynard,et al.  Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. , 2003, Journal of hepatology.

[32]  R. Testa,et al.  Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. , 2003, Archives of internal medicine.

[33]  Llorenç Quintó,et al.  Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model , 2002, Hepatology.

[34]  E. Schiff,et al.  Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection , 2002, American Journal of Gastroenterology.

[35]  J. Phair,et al.  HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) , 2002, The Lancet.

[36]  R. Paredes,et al.  Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  T. Poynard,et al.  Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study , 2001, The Lancet.

[38]  F. Donato,et al.  Mortality for liver disease in patients with HIV infection: a cohort study. , 2000, Journal of acquired immune deficiency syndromes.

[39]  M. Manns,et al.  Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. , 1997, Journal of hepatology.

[40]  P. Bedossa,et al.  An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.

[41]  A. Pesce,et al.  Circulating anticoagulant in patients seropositive for human immunodeficiency virus. , 1989, American Journal of Medicine.

[42]  J. Hanley,et al.  Statistical Approaches to the Analysis of Receiver Operating Characteristic (ROC) Curves , 1984, Medical decision making : an international journal of the Society for Medical Decision Making.

[43]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[44]  B. Balkau,et al.  Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. , 1994, Journal of hepatology.